Amgen, Cytokinetics to Continue Phase 3 Heart Failure Trial

Date : 02/26/2020 @ 3:04PM
Source : Dow Jones News
Stock : Amgen Inc (AMGN)
Quote : 208.88  0.0 (0.00%) @ 9:31AM
Amgen share price Chart

Amgen, Cytokinetics to Continue Phase 3 Heart Failure Trial

Historical Stock Chart

2 Months : From Feb 2020 to Apr 2020

Click Here for more Amgen Charts.

By Michael Dabaie


Amgen Inc., Cytokinetics Inc. and Servier said they would continue the GALACTIC-HF Phase 3 heart failure trial following a planned interim analysis.

The companies said the Data Monitoring Committee recommended the Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure continue without changes.

Topline results are expected in the fourth quarter of 2020.

GALACTIC-HF completed enrollment of more than 8,200 patients in 35 countries who were either hospitalized at the time of enrollment for a primary reason of heart failure, or had a hospitalization or admission to an emergency room for heart failure within one year prior to screening.

Omecamtiv mecarbil is being developed by Amgen in collaboration with Cytokinetics, with funding and strategic support from Servier.


Write to Michael Dabaie at


(END) Dow Jones Newswires

February 26, 2020 09:49 ET (14:49 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Latest AMGN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20200403 08:56:04